Answers are grounded in this paper and cite their sources.
Endometrial microbiota studies in gynecologic cancer remain difficult to interpret because the uterine cavity is a low-biomass environment prone to contamination and strong spatial heterogeneity. In this prospective case-control study, we performed multi-site ex vivo sampling of postmenopausal women undergoing hysterectomy for endometrial carcinoma (n = 17) or uterine prolapse (n = 16), with matched cervicovaginal, anorectal, and negative controls, followed by V3–V4 16S rRNA gene sequencing and stringent contaminant filtering. After removal of likely contaminants, 897 bacterial sequence variants remained, revealing sparse and heterogeneous bacterial DNA profiles in endometrial specimens. Tumor-associated endometrial microbiota composition was more similar to patient-matched cervicovaginal profiles than were non-tumor endometrial profiles, and this similarity pattern was patient-specific rather than driven by a consistent set of taxa. Differences between cancer and control groups were modest; biopsy specimens from cancer cases showed higher richness than controls, while swab specimens did not. No individual taxa met criteria for robust endometrial cancer-associated biomarkers. These findings indicate that the endometrial microbiota in endometrial carcinoma is weakly structured by disease status and dominated by inter-individual and anatomical variability. Our results indicate that the low-biomass endometrial microbiota in endometrial carcinoma is predominantly sparse and weakly structured by oncological status. Tumor-associated communities closely mirror patient-specific cervicovaginal profiles, underscoring the necessity of anatomy-aware sampling and contamination-controlled sampling in gynecologic oncobiome research.
No takes yet. Share an insight, caveat, or question.
Poberžnik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: